Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NYSE:HNGR NASDAQ:IMAC NASDAQ:KYMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.46+1.9%$15.03$11.51▼$21.50$3.05B0.5291,717 shs11,336 shsHNGRHanger$18.72$18.70$13.42▼$22.67$732.38M1.28356,429 shsN/AIMACIMAC$0.07+1.8%$0.05$0.75▼$1.65$1.77M-0.88708,132 shs6,424 shsKYMRKymera Therapeutics$46.23+1.6%$40.35$19.45▼$53.27$3.01B2.18618,360 shs125,859 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+3.44%+5.09%+2.03%+24.49%-8.15%HNGRHanger0.00%0.00%0.00%0.00%0.00%IMACIMAC-18.53%-3.90%+54.82%+45.58%-96.26%KYMRKymera Therapeutics+1.34%+0.73%-2.84%+75.24%-6.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED1.6162 of 5 stars2.03.00.00.02.50.01.9HNGRHangerN/AN/AN/AN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AN/AN/AN/AKYMRKymera Therapeutics2.9659 of 5 stars4.51.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$19.008.81% UpsideHNGRHanger 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/AKYMRKymera Therapeutics 3.00Buy$59.1127.88% UpsideCurrent Analyst Ratings BreakdownLatest HNGR, IMAC, KYMR, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.83$0.30 per share57.65$4.43 per share3.94HNGRHanger$1.12B0.65$1.88 per share9.98$2.85 per share6.57IMACIMAC$15.22M0.12N/AN/A$0.69 per share0.10KYMRKymera Therapeutics$47.07M63.95N/AN/A$12.90 per share3.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0011.96N/AN/AN/AN/A8/7/2025 (Estimated)HNGRHanger$41.98M$0.9519.7115.60N/A3.17%35.72%4.00%N/AIMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AKYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)Latest HNGR, IMAC, KYMR, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025KYMRKymera Therapeutics-$0.84N/AN/AN/A$17.37 millionN/A5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AHNGRHangerN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.082.832.70HNGRHanger3.711.230.85IMACIMAC0.011.271.27KYMRKymera TherapeuticsN/A8.498.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%HNGRHanger79.17%IMACIMAC24.27%KYMRKymera TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%HNGRHanger4.36%IMACIMAC10.00%KYMRKymera Therapeutics16.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableHNGRHanger5,20039.12 million37.42 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableHNGR, IMAC, KYMR, and HCM HeadlinesRecent News About These CompaniesKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from AnalystsJuly 17 at 4:31 AM | marketbeat.comKymera Therapeutics Inc (KYMR) - Investing.comJuly 11, 2025 | investing.comBrookline Capital Management Comments on KYMR Q3 EarningsJuly 10, 2025 | americanbankingnews.comQ3 EPS Estimate for Kymera Therapeutics Raised by AnalystJuly 9, 2025 | marketbeat.comKymera Therapeutics (KYMR) director group buys $13.9 million in stockJuly 3, 2025 | investing.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan StanleyJuly 3, 2025 | marketbeat.comTuesday’s Insider Activity: Major Buys and Sells Shake Up MarketsJuly 3, 2025 | investing.comInsider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of StockJuly 2, 2025 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 SharesJuly 1, 2025 | marketbeat.comBros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) StockJuly 1, 2025 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Buys 655,500 SharesJune 30, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for KYMR FY2026 EarningsJune 30, 2025 | marketbeat.comKYMR Q3 EPS Estimate Reduced by Brookline Capital ManagementJune 30, 2025 | marketbeat.comOppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00June 27, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?June 27, 2025 | marketbeat.comKymera Therapeutics Announces Pricing of $250 Million Public OfferingJune 26, 2025 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% Following Analyst DowngradeJune 26, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Lowered to $53.00 at Wells Fargo & CompanyJune 26, 2025 | marketbeat.comKYMR Collaborates With GILD; Stock Down on Sanofi Deal UpdateJune 26, 2025 | zacks.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC WainwrightJune 26, 2025 | marketbeat.comKYMR Kymera Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHNGR, IMAC, KYMR, and HCM Company DescriptionsHUTCHMED NASDAQ:HCM$17.46 +0.33 (+1.94%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Hanger NYSE:HNGRHanger, Inc. provides orthotic and prosthetic (O&P) services in the United States. It operates in two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and offers payor network contracting services to other O&P providers. The Products & Services segment engages in the distribution of various O&P parts, componentry, and devices to independent O&P providers; development of specialized rehabilitation technologies; and provision of evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2021, the company operated approximately 760 patient care clinics and 115 satellite locations in 47 states and the District of Columbia. It also distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings. The company was formerly known as Hanger Orthopedic Group, Inc. and changed its name to Hanger, Inc. in June 2012. Hanger, Inc. was founded in 1861 and is headquartered in Austin, Texas.IMAC NASDAQ:IMAC$0.07 +0.00 (+1.82%) As of 07/16/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Kymera Therapeutics NASDAQ:KYMR$46.22 +0.72 (+1.57%) As of 01:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
